KR101161823B1 - 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체 - Google Patents

세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체 Download PDF

Info

Publication number
KR101161823B1
KR101161823B1 KR1020057020664A KR20057020664A KR101161823B1 KR 101161823 B1 KR101161823 B1 KR 101161823B1 KR 1020057020664 A KR1020057020664 A KR 1020057020664A KR 20057020664 A KR20057020664 A KR 20057020664A KR 101161823 B1 KR101161823 B1 KR 101161823B1
Authority
KR
South Korea
Prior art keywords
delete delete
dalda
cells
dmt
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057020664A
Other languages
English (en)
Korean (ko)
Other versions
KR20060008950A (ko
Inventor
하젤 제토
케쉥 자오
알렉스 브이 버크
휴 디 로버트슨
Original Assignee
코넬 리서치 화운데이션,인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코넬 리서치 화운데이션,인크. filed Critical 코넬 리서치 화운데이션,인크.
Publication of KR20060008950A publication Critical patent/KR20060008950A/ko
Application granted granted Critical
Publication of KR101161823B1 publication Critical patent/KR101161823B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020057020664A 2003-05-01 2004-05-03 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체 Expired - Fee Related KR101161823B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46751603P 2003-05-01 2003-05-01
US60/467,516 2003-05-01
PCT/US2004/013772 WO2005001023A2 (en) 2003-05-01 2004-05-03 Method and carrier complexes for delivering molecules to cells

Publications (2)

Publication Number Publication Date
KR20060008950A KR20060008950A (ko) 2006-01-27
KR101161823B1 true KR101161823B1 (ko) 2012-07-03

Family

ID=33551404

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057020664A Expired - Fee Related KR101161823B1 (ko) 2003-05-01 2004-05-03 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체

Country Status (17)

Country Link
US (6) US7704954B2 (enExample)
EP (7) EP3167935B1 (enExample)
JP (6) JP4879020B2 (enExample)
KR (1) KR101161823B1 (enExample)
CN (2) CN100506841C (enExample)
AU (1) AU2004252419B2 (enExample)
BR (1) BRPI0409911A (enExample)
CA (1) CA2524258C (enExample)
DK (4) DK2604286T3 (enExample)
ES (3) ES2694574T3 (enExample)
MX (1) MXPA05011773A (enExample)
NZ (1) NZ543410A (enExample)
PL (2) PL2604285T3 (enExample)
PT (2) PT2604285E (enExample)
SI (1) SI2604285T1 (enExample)
WO (1) WO2005001023A2 (enExample)
ZA (1) ZA200509229B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062788A (ko) * 2002-01-19 2003-07-28 포휴먼텍(주) 생체분자 전달 펩타이드 ｍｐｈ1-ｂｔｍ 및 이것을포함하는 생명공학제품
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US7534819B2 (en) * 2005-06-10 2009-05-19 University Of Washington Compositions and methods for intracellular delivery of biotinylated cargo
AU2006292352B2 (en) 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
DE602006016468D1 (de) * 2005-11-04 2010-10-07 Forhumantech Co Ltd Verfahren zur abgabe von fusionspolypeptid in eine zelle
KR101574630B1 (ko) * 2006-07-24 2015-12-07 (주)앰브로시아 허혈성 질환의 완화 및 치료를 위한 약학 조성물 및 그를 전달하기 위한 방법
CN101511872A (zh) * 2006-08-29 2009-08-19 为人技术株式会社 用于抑制凋亡的药物组合物及其递送方法
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
EP2252312B1 (en) 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
DK2464371T3 (en) * 2009-08-12 2016-06-27 Univ Cornell Methods for preventing or treating metabolic syndrome
WO2011025734A1 (en) 2009-08-24 2011-03-03 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
US20110082084A1 (en) * 2009-10-05 2011-04-07 Szeto Hazel H Methods for the prevention or treatment of heart failure
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP2566880A4 (en) * 2010-05-03 2014-10-08 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
GB201018125D0 (en) 2010-10-26 2010-12-08 Marealis As Peptide
WO2012129427A2 (en) * 2011-03-24 2012-09-27 Cornell University Aromatic-cationic peptides and uses of same
US20150118315A1 (en) * 2011-06-14 2015-04-30 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
JP6025311B2 (ja) 2011-08-01 2016-11-16 キヤノン株式会社 眼科診断支援装置および方法
CN103987397A (zh) 2011-09-29 2014-08-13 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CA2852454A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
EP2788013A4 (en) 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
CA2870200A1 (en) * 2012-04-12 2013-10-17 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2880643A1 (en) 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
EP2989120A4 (en) 2013-04-25 2017-04-19 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
US20170081363A1 (en) * 2014-03-03 2017-03-23 Stealth Biotherapeutics Corp Pharmaceutically relevant aromatic-cationic peptides
US20170182117A1 (en) * 2014-05-28 2017-06-29 Stealth Biotherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
WO2015183995A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
SI3160984T1 (sl) 2014-06-25 2021-08-31 Flamma S.P.A. Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
US10112976B2 (en) 2014-06-30 2018-10-30 Flamma S.P.A. Process for the production of D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
WO2016209261A1 (en) * 2015-06-26 2016-12-29 Stealth Biotherapeutics Corp Therapeutic compositions including gramicidin s peptidyl conjugates or imidazole-substituted fatty acids, variants thereof, and uses thereof
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
CA3039906A1 (en) * 2015-10-21 2017-04-27 The Regents Of The University Of Michigan Detection and treatment of caries and microcavities with nanoparticles
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
JP7218897B2 (ja) 2016-11-16 2023-02-07 ルカ・サイエンス株式会社 心不全の治療及び／又は予防に用いるための心筋幹細胞の製造方法
US20190380958A1 (en) * 2016-12-28 2019-12-19 Chugai Seiyaku Kabushiki Kaisha Self-emulsifying drug formulation for improving membrane permeability of compound
CN107230021B (zh) * 2017-06-08 2020-05-26 桂林理工大学 筛选供水管网泄漏区域的方法
JP2021529163A (ja) * 2018-06-29 2021-10-28 グリコス バイオメディカル オーワイ コンジュゲート
JP2023508779A (ja) 2019-12-27 2023-03-03 ルカ・サイエンス株式会社 サイズがより小さい単離されたミトコンドリアおよび単離されたミトコンドリアを内包している脂質膜ベースの小胞
WO2021216499A1 (en) * 2020-04-23 2021-10-28 North Carolina State University Cell-penetrating peptide-microrna conjugates for intracellular cell delivery
GB2614162B (en) 2020-09-09 2024-11-06 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1979000515A1 (en) * 1978-01-16 1979-08-09 Univ Boston Method of effecting cellular uptake of molecules
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ATE136905T1 (de) 1988-06-30 1996-05-15 Astra Ab Dermorphin-analoge, deren herstellungsverfahren, pharmazeutische zusammensetzungen und methode zur therapeutischen behandlung unter verwendung der analoge
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5169934A (en) * 1990-05-14 1992-12-08 Anergen, Inc. Intracellularly cleavable compounds
NL9001639A (nl) 1990-07-19 1992-02-17 Amc Amsterdam Pt-houdende verbinding, werkwijze voor de bereiding ervan, alsmede toepassing van dergelijke verbindingen.
US5714327A (en) 1990-07-19 1998-02-03 Kreatech Diagnostics Platinum-containing compounds, methods for their preparation and applications thereof
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5747026A (en) * 1993-10-15 1998-05-05 University Of Alabama At Birmingham Research Foundation Antioxidants
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6221355B1 (en) 1997-12-10 2001-04-24 Washington University Anti-pathogen system and methods of use thereof
WO1999055321A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
AU7856600A (en) 1999-10-04 2001-05-10 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
GB0005703D0 (en) * 2000-03-09 2000-05-03 Alpharma As Compounds
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
GB0026924D0 (en) * 2000-11-03 2000-12-20 Univ Cambridge Tech Antibacterial agents
EP1401473B1 (en) * 2001-02-16 2009-07-29 Cellgate Inc. Transporters comprising spaced arginine moieties
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
US20070015146A1 (en) 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
ES2436011T3 (es) * 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
AU2006292352B2 (en) 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
US20070259377A1 (en) 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
US20080027082A1 (en) 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP2252312B1 (en) 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
CN112639591B (zh) 2018-06-29 2025-06-06 瑞尔D斯帕克有限责任公司 隐私显示的稳定化

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antimicrobial Agents and Chemotherapy, 제40권, 제8호, 제1801-1805면 (1996년)

Also Published As

Publication number Publication date
DK2604285T3 (en) 2014-12-01
BRPI0409911A (pt) 2006-04-25
ES2520816T3 (es) 2014-11-11
DK1625149T3 (en) 2016-05-30
KR20060008950A (ko) 2006-01-27
US20050158373A1 (en) 2005-07-21
DK2604621T3 (en) 2016-02-01
US20220372172A1 (en) 2022-11-24
US8148322B2 (en) 2012-04-03
EP2604621B1 (en) 2015-10-21
EP1625149A2 (en) 2006-02-15
JP2018158951A (ja) 2018-10-11
JP6698756B2 (ja) 2020-05-27
US20130085259A1 (en) 2013-04-04
US11845807B2 (en) 2023-12-19
US20200299415A1 (en) 2020-09-24
HK1231424A1 (en) 2017-12-22
US20170035899A1 (en) 2017-02-09
CN1780851A (zh) 2006-05-31
EP3381515A1 (en) 2018-10-03
JP6395749B2 (ja) 2018-09-26
DK2604286T3 (en) 2014-12-08
PT2604286E (pt) 2014-11-28
HK1186407A1 (en) 2014-03-14
JP2014221846A (ja) 2014-11-27
EP2604286B1 (en) 2014-08-27
HK1186482A1 (en) 2014-03-14
WO2005001023A3 (en) 2005-04-28
ZA200509229B (en) 2007-03-28
US7704954B2 (en) 2010-04-27
CN100506841C (zh) 2009-07-01
PL2604285T3 (pl) 2015-02-27
PT2604285E (pt) 2014-11-12
EP2604285A1 (en) 2013-06-19
ES2520815T3 (es) 2014-11-11
US10584182B2 (en) 2020-03-10
ES2694574T3 (es) 2018-12-21
JP5995930B2 (ja) 2016-09-21
EP2604285B1 (en) 2014-08-27
JP2016130246A (ja) 2016-07-21
JP4879020B2 (ja) 2012-02-15
JP2011168603A (ja) 2011-09-01
HK1186406A1 (en) 2014-03-14
EP2604286A1 (en) 2013-06-19
HK1089450A1 (zh) 2006-12-01
AU2004252419B2 (en) 2010-02-18
SI2604285T1 (sl) 2014-12-31
EP2604287B1 (en) 2016-12-07
CA2524258C (en) 2012-08-07
AU2004252419A1 (en) 2005-01-06
NZ543410A (en) 2008-07-31
EP1625149A4 (en) 2010-10-06
EP1625149B1 (en) 2016-02-17
HK1253888A1 (en) 2019-07-05
WO2005001023A2 (en) 2005-01-06
MXPA05011773A (es) 2006-02-17
EP3167935A1 (en) 2017-05-17
JP2007503461A (ja) 2007-02-22
US20100204448A1 (en) 2010-08-12
EP2604621A1 (en) 2013-06-19
EP2604287A3 (en) 2014-04-16
JP2020105184A (ja) 2020-07-09
US11180574B2 (en) 2021-11-23
EP3381515B1 (en) 2020-07-08
US9315586B2 (en) 2016-04-19
EP3167935B1 (en) 2018-07-18
EP2604287A2 (en) 2013-06-19
JP5650040B2 (ja) 2015-01-07
CA2524258A1 (en) 2005-01-06
CN101214380A (zh) 2008-07-09
PL2604286T3 (pl) 2015-03-31

Similar Documents

Publication Publication Date Title
KR101161823B1 (ko) 세포로 분자를 전달하는 방법 및 이것을 위한 캐리어 복합체
HK1253888B (en) Carrier complexes for delivering molecules to cells
HK1186405A (en) Method and carrier complexes for delivering molecules to cells
HK1121683A (en) Method and carrier complexes for delivering molecules to cells
HK1089450B (en) Method and carrier complexes for delivering molecules to cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20150608

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20160616

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20170614

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20180614

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20190614

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200627

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200627